torin2 Search Results


torin 2  (MedChemExpress)
93
MedChemExpress torin 2
A-B) Growth curves (A) and end point viability (B) of TEADi-sensitive or -resistant meningioma cell lines upon co-treatment with combinations of TEADi (IAG-933, 200 nM (sensitive lines) or 500 nM (resistant lines)), PI3Ki (pictilisib, 50 nM), MEKi (trametinib), or mTORi <t>(torin-2).</t> All experiments were performed in triplicates. C) Synergy plots for TEADi/MEKi or TEADi/mTORi combination treatments of TEADi-sensitive (KT21-MG1) or -resistant (IOMM-Lee) meningioma cell lines. D) Western Blot showing activation of MAPK (p-ERK), PI3K-AKT (p-AKT), or mTOR-S6 (p-S6) pathways in TEADi-resistant IOMM-Lee cells upon treatment with TEADi (IAG-933), MEKi (trametinib), mTORi (torin-2), or PI3Ki (pictilisib) in various combinations. Actin was used as a loading control. E) Growth curves of TEADi-resistant CH-157MN cells upon treatment with TEADi (IAG-933, 200 nM) or additional mTOR inhibitors (torin-2, rapamycin, vistusertib, everolimus, sapanisertib, 10 nM each). All experiments were performed in triplicates. F) End point viability of TEADi-sensitive and -resistant cell lines upon treatment with TEADi (IAG-933, 200 nM) or FAKi (TAE226, 500 nM). Error bars show SEM (A, B, E, F). Analysis was done using an ordinary one-way ANOVA (B,F) or ordinary two-way ANOVA (A, E, comparison at last time point) with multiple comparisons testing. Synergy analysis for two-way treatments was done with SynergyFinder3.0.
Torin 2, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/torin 2/product/MedChemExpress
Average 93 stars, based on 1 article reviews
torin 2 - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
868 torin2  (TargetMol)
92
TargetMol 868 torin2
A-B) Growth curves (A) and end point viability (B) of TEADi-sensitive or -resistant meningioma cell lines upon co-treatment with combinations of TEADi (IAG-933, 200 nM (sensitive lines) or 500 nM (resistant lines)), PI3Ki (pictilisib, 50 nM), MEKi (trametinib), or mTORi <t>(torin-2).</t> All experiments were performed in triplicates. C) Synergy plots for TEADi/MEKi or TEADi/mTORi combination treatments of TEADi-sensitive (KT21-MG1) or -resistant (IOMM-Lee) meningioma cell lines. D) Western Blot showing activation of MAPK (p-ERK), PI3K-AKT (p-AKT), or mTOR-S6 (p-S6) pathways in TEADi-resistant IOMM-Lee cells upon treatment with TEADi (IAG-933), MEKi (trametinib), mTORi (torin-2), or PI3Ki (pictilisib) in various combinations. Actin was used as a loading control. E) Growth curves of TEADi-resistant CH-157MN cells upon treatment with TEADi (IAG-933, 200 nM) or additional mTOR inhibitors (torin-2, rapamycin, vistusertib, everolimus, sapanisertib, 10 nM each). All experiments were performed in triplicates. F) End point viability of TEADi-sensitive and -resistant cell lines upon treatment with TEADi (IAG-933, 200 nM) or FAKi (TAE226, 500 nM). Error bars show SEM (A, B, E, F). Analysis was done using an ordinary one-way ANOVA (B,F) or ordinary two-way ANOVA (A, E, comparison at last time point) with multiple comparisons testing. Synergy analysis for two-way treatments was done with SynergyFinder3.0.
868 Torin2, supplied by TargetMol, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/868 torin2/product/TargetMol
Average 92 stars, based on 1 article reviews
868 torin2 - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier
torin2  (Selleck Chemicals)
93
Selleck Chemicals torin2
A-B) Growth curves (A) and end point viability (B) of TEADi-sensitive or -resistant meningioma cell lines upon co-treatment with combinations of TEADi (IAG-933, 200 nM (sensitive lines) or 500 nM (resistant lines)), PI3Ki (pictilisib, 50 nM), MEKi (trametinib), or mTORi <t>(torin-2).</t> All experiments were performed in triplicates. C) Synergy plots for TEADi/MEKi or TEADi/mTORi combination treatments of TEADi-sensitive (KT21-MG1) or -resistant (IOMM-Lee) meningioma cell lines. D) Western Blot showing activation of MAPK (p-ERK), PI3K-AKT (p-AKT), or mTOR-S6 (p-S6) pathways in TEADi-resistant IOMM-Lee cells upon treatment with TEADi (IAG-933), MEKi (trametinib), mTORi (torin-2), or PI3Ki (pictilisib) in various combinations. Actin was used as a loading control. E) Growth curves of TEADi-resistant CH-157MN cells upon treatment with TEADi (IAG-933, 200 nM) or additional mTOR inhibitors (torin-2, rapamycin, vistusertib, everolimus, sapanisertib, 10 nM each). All experiments were performed in triplicates. F) End point viability of TEADi-sensitive and -resistant cell lines upon treatment with TEADi (IAG-933, 200 nM) or FAKi (TAE226, 500 nM). Error bars show SEM (A, B, E, F). Analysis was done using an ordinary one-way ANOVA (B,F) or ordinary two-way ANOVA (A, E, comparison at last time point) with multiple comparisons testing. Synergy analysis for two-way treatments was done with SynergyFinder3.0.
Torin2, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/torin2/product/Selleck Chemicals
Average 93 stars, based on 1 article reviews
torin2 - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
torin 2  (Tocris)
94
Tocris torin 2
A-B) Growth curves (A) and end point viability (B) of TEADi-sensitive or -resistant meningioma cell lines upon co-treatment with combinations of TEADi (IAG-933, 200 nM (sensitive lines) or 500 nM (resistant lines)), PI3Ki (pictilisib, 50 nM), MEKi (trametinib), or mTORi <t>(torin-2).</t> All experiments were performed in triplicates. C) Synergy plots for TEADi/MEKi or TEADi/mTORi combination treatments of TEADi-sensitive (KT21-MG1) or -resistant (IOMM-Lee) meningioma cell lines. D) Western Blot showing activation of MAPK (p-ERK), PI3K-AKT (p-AKT), or mTOR-S6 (p-S6) pathways in TEADi-resistant IOMM-Lee cells upon treatment with TEADi (IAG-933), MEKi (trametinib), mTORi (torin-2), or PI3Ki (pictilisib) in various combinations. Actin was used as a loading control. E) Growth curves of TEADi-resistant CH-157MN cells upon treatment with TEADi (IAG-933, 200 nM) or additional mTOR inhibitors (torin-2, rapamycin, vistusertib, everolimus, sapanisertib, 10 nM each). All experiments were performed in triplicates. F) End point viability of TEADi-sensitive and -resistant cell lines upon treatment with TEADi (IAG-933, 200 nM) or FAKi (TAE226, 500 nM). Error bars show SEM (A, B, E, F). Analysis was done using an ordinary one-way ANOVA (B,F) or ordinary two-way ANOVA (A, E, comparison at last time point) with multiple comparisons testing. Synergy analysis for two-way treatments was done with SynergyFinder3.0.
Torin 2, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/torin 2/product/Tocris
Average 94 stars, based on 1 article reviews
torin 2 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
torin2  (Cell Signaling Technology Inc)
93
Cell Signaling Technology Inc torin2
A-B) Growth curves (A) and end point viability (B) of TEADi-sensitive or -resistant meningioma cell lines upon co-treatment with combinations of TEADi (IAG-933, 200 nM (sensitive lines) or 500 nM (resistant lines)), PI3Ki (pictilisib, 50 nM), MEKi (trametinib), or mTORi <t>(torin-2).</t> All experiments were performed in triplicates. C) Synergy plots for TEADi/MEKi or TEADi/mTORi combination treatments of TEADi-sensitive (KT21-MG1) or -resistant (IOMM-Lee) meningioma cell lines. D) Western Blot showing activation of MAPK (p-ERK), PI3K-AKT (p-AKT), or mTOR-S6 (p-S6) pathways in TEADi-resistant IOMM-Lee cells upon treatment with TEADi (IAG-933), MEKi (trametinib), mTORi (torin-2), or PI3Ki (pictilisib) in various combinations. Actin was used as a loading control. E) Growth curves of TEADi-resistant CH-157MN cells upon treatment with TEADi (IAG-933, 200 nM) or additional mTOR inhibitors (torin-2, rapamycin, vistusertib, everolimus, sapanisertib, 10 nM each). All experiments were performed in triplicates. F) End point viability of TEADi-sensitive and -resistant cell lines upon treatment with TEADi (IAG-933, 200 nM) or FAKi (TAE226, 500 nM). Error bars show SEM (A, B, E, F). Analysis was done using an ordinary one-way ANOVA (B,F) or ordinary two-way ANOVA (A, E, comparison at last time point) with multiple comparisons testing. Synergy analysis for two-way treatments was done with SynergyFinder3.0.
Torin2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/torin2/product/Cell Signaling Technology Inc
Average 93 stars, based on 1 article reviews
torin2 - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
torin2  (Chemdea LLC)
90
Chemdea LLC torin2
A-B) Growth curves (A) and end point viability (B) of TEADi-sensitive or -resistant meningioma cell lines upon co-treatment with combinations of TEADi (IAG-933, 200 nM (sensitive lines) or 500 nM (resistant lines)), PI3Ki (pictilisib, 50 nM), MEKi (trametinib), or mTORi <t>(torin-2).</t> All experiments were performed in triplicates. C) Synergy plots for TEADi/MEKi or TEADi/mTORi combination treatments of TEADi-sensitive (KT21-MG1) or -resistant (IOMM-Lee) meningioma cell lines. D) Western Blot showing activation of MAPK (p-ERK), PI3K-AKT (p-AKT), or mTOR-S6 (p-S6) pathways in TEADi-resistant IOMM-Lee cells upon treatment with TEADi (IAG-933), MEKi (trametinib), mTORi (torin-2), or PI3Ki (pictilisib) in various combinations. Actin was used as a loading control. E) Growth curves of TEADi-resistant CH-157MN cells upon treatment with TEADi (IAG-933, 200 nM) or additional mTOR inhibitors (torin-2, rapamycin, vistusertib, everolimus, sapanisertib, 10 nM each). All experiments were performed in triplicates. F) End point viability of TEADi-sensitive and -resistant cell lines upon treatment with TEADi (IAG-933, 200 nM) or FAKi (TAE226, 500 nM). Error bars show SEM (A, B, E, F). Analysis was done using an ordinary one-way ANOVA (B,F) or ordinary two-way ANOVA (A, E, comparison at last time point) with multiple comparisons testing. Synergy analysis for two-way treatments was done with SynergyFinder3.0.
Torin2, supplied by Chemdea LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/torin2/product/Chemdea LLC
Average 90 stars, based on 1 article reviews
torin2 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
torin-2  (Cayman Chemical)
90
Cayman Chemical torin-2
A-B) Growth curves (A) and end point viability (B) of TEADi-sensitive or -resistant meningioma cell lines upon co-treatment with combinations of TEADi (IAG-933, 200 nM (sensitive lines) or 500 nM (resistant lines)), PI3Ki (pictilisib, 50 nM), MEKi (trametinib), or mTORi <t>(torin-2).</t> All experiments were performed in triplicates. C) Synergy plots for TEADi/MEKi or TEADi/mTORi combination treatments of TEADi-sensitive (KT21-MG1) or -resistant (IOMM-Lee) meningioma cell lines. D) Western Blot showing activation of MAPK (p-ERK), PI3K-AKT (p-AKT), or mTOR-S6 (p-S6) pathways in TEADi-resistant IOMM-Lee cells upon treatment with TEADi (IAG-933), MEKi (trametinib), mTORi (torin-2), or PI3Ki (pictilisib) in various combinations. Actin was used as a loading control. E) Growth curves of TEADi-resistant CH-157MN cells upon treatment with TEADi (IAG-933, 200 nM) or additional mTOR inhibitors (torin-2, rapamycin, vistusertib, everolimus, sapanisertib, 10 nM each). All experiments were performed in triplicates. F) End point viability of TEADi-sensitive and -resistant cell lines upon treatment with TEADi (IAG-933, 200 nM) or FAKi (TAE226, 500 nM). Error bars show SEM (A, B, E, F). Analysis was done using an ordinary one-way ANOVA (B,F) or ordinary two-way ANOVA (A, E, comparison at last time point) with multiple comparisons testing. Synergy analysis for two-way treatments was done with SynergyFinder3.0.
Torin 2, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/torin-2/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
torin-2 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
torin 2  (Cayman Chemical)
90
Cayman Chemical torin 2
A-B) Growth curves (A) and end point viability (B) of TEADi-sensitive or -resistant meningioma cell lines upon co-treatment with combinations of TEADi (IAG-933, 200 nM (sensitive lines) or 500 nM (resistant lines)), PI3Ki (pictilisib, 50 nM), MEKi (trametinib), or mTORi <t>(torin-2).</t> All experiments were performed in triplicates. C) Synergy plots for TEADi/MEKi or TEADi/mTORi combination treatments of TEADi-sensitive (KT21-MG1) or -resistant (IOMM-Lee) meningioma cell lines. D) Western Blot showing activation of MAPK (p-ERK), PI3K-AKT (p-AKT), or mTOR-S6 (p-S6) pathways in TEADi-resistant IOMM-Lee cells upon treatment with TEADi (IAG-933), MEKi (trametinib), mTORi (torin-2), or PI3Ki (pictilisib) in various combinations. Actin was used as a loading control. E) Growth curves of TEADi-resistant CH-157MN cells upon treatment with TEADi (IAG-933, 200 nM) or additional mTOR inhibitors (torin-2, rapamycin, vistusertib, everolimus, sapanisertib, 10 nM each). All experiments were performed in triplicates. F) End point viability of TEADi-sensitive and -resistant cell lines upon treatment with TEADi (IAG-933, 200 nM) or FAKi (TAE226, 500 nM). Error bars show SEM (A, B, E, F). Analysis was done using an ordinary one-way ANOVA (B,F) or ordinary two-way ANOVA (A, E, comparison at last time point) with multiple comparisons testing. Synergy analysis for two-way treatments was done with SynergyFinder3.0.
Torin 2, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/torin 2/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
torin 2 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
torin 2  (Biomarine Nitron)
90
Biomarine Nitron torin 2
A-B) Growth curves (A) and end point viability (B) of TEADi-sensitive or -resistant meningioma cell lines upon co-treatment with combinations of TEADi (IAG-933, 200 nM (sensitive lines) or 500 nM (resistant lines)), PI3Ki (pictilisib, 50 nM), MEKi (trametinib), or mTORi <t>(torin-2).</t> All experiments were performed in triplicates. C) Synergy plots for TEADi/MEKi or TEADi/mTORi combination treatments of TEADi-sensitive (KT21-MG1) or -resistant (IOMM-Lee) meningioma cell lines. D) Western Blot showing activation of MAPK (p-ERK), PI3K-AKT (p-AKT), or mTOR-S6 (p-S6) pathways in TEADi-resistant IOMM-Lee cells upon treatment with TEADi (IAG-933), MEKi (trametinib), mTORi (torin-2), or PI3Ki (pictilisib) in various combinations. Actin was used as a loading control. E) Growth curves of TEADi-resistant CH-157MN cells upon treatment with TEADi (IAG-933, 200 nM) or additional mTOR inhibitors (torin-2, rapamycin, vistusertib, everolimus, sapanisertib, 10 nM each). All experiments were performed in triplicates. F) End point viability of TEADi-sensitive and -resistant cell lines upon treatment with TEADi (IAG-933, 200 nM) or FAKi (TAE226, 500 nM). Error bars show SEM (A, B, E, F). Analysis was done using an ordinary one-way ANOVA (B,F) or ordinary two-way ANOVA (A, E, comparison at last time point) with multiple comparisons testing. Synergy analysis for two-way treatments was done with SynergyFinder3.0.
Torin 2, supplied by Biomarine Nitron, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/torin 2/product/Biomarine Nitron
Average 90 stars, based on 1 article reviews
torin 2 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
torin2  (ApexBio)
90
ApexBio torin2
A-B) Growth curves (A) and end point viability (B) of TEADi-sensitive or -resistant meningioma cell lines upon co-treatment with combinations of TEADi (IAG-933, 200 nM (sensitive lines) or 500 nM (resistant lines)), PI3Ki (pictilisib, 50 nM), MEKi (trametinib), or mTORi <t>(torin-2).</t> All experiments were performed in triplicates. C) Synergy plots for TEADi/MEKi or TEADi/mTORi combination treatments of TEADi-sensitive (KT21-MG1) or -resistant (IOMM-Lee) meningioma cell lines. D) Western Blot showing activation of MAPK (p-ERK), PI3K-AKT (p-AKT), or mTOR-S6 (p-S6) pathways in TEADi-resistant IOMM-Lee cells upon treatment with TEADi (IAG-933), MEKi (trametinib), mTORi (torin-2), or PI3Ki (pictilisib) in various combinations. Actin was used as a loading control. E) Growth curves of TEADi-resistant CH-157MN cells upon treatment with TEADi (IAG-933, 200 nM) or additional mTOR inhibitors (torin-2, rapamycin, vistusertib, everolimus, sapanisertib, 10 nM each). All experiments were performed in triplicates. F) End point viability of TEADi-sensitive and -resistant cell lines upon treatment with TEADi (IAG-933, 200 nM) or FAKi (TAE226, 500 nM). Error bars show SEM (A, B, E, F). Analysis was done using an ordinary one-way ANOVA (B,F) or ordinary two-way ANOVA (A, E, comparison at last time point) with multiple comparisons testing. Synergy analysis for two-way treatments was done with SynergyFinder3.0.
Torin2, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/torin2/product/ApexBio
Average 90 stars, based on 1 article reviews
torin2 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
torin 2 cayman 14185  (Cayman Chemical)
90
Cayman Chemical torin 2 cayman 14185
A-B) Growth curves (A) and end point viability (B) of TEADi-sensitive or -resistant meningioma cell lines upon co-treatment with combinations of TEADi (IAG-933, 200 nM (sensitive lines) or 500 nM (resistant lines)), PI3Ki (pictilisib, 50 nM), MEKi (trametinib), or mTORi <t>(torin-2).</t> All experiments were performed in triplicates. C) Synergy plots for TEADi/MEKi or TEADi/mTORi combination treatments of TEADi-sensitive (KT21-MG1) or -resistant (IOMM-Lee) meningioma cell lines. D) Western Blot showing activation of MAPK (p-ERK), PI3K-AKT (p-AKT), or mTOR-S6 (p-S6) pathways in TEADi-resistant IOMM-Lee cells upon treatment with TEADi (IAG-933), MEKi (trametinib), mTORi (torin-2), or PI3Ki (pictilisib) in various combinations. Actin was used as a loading control. E) Growth curves of TEADi-resistant CH-157MN cells upon treatment with TEADi (IAG-933, 200 nM) or additional mTOR inhibitors (torin-2, rapamycin, vistusertib, everolimus, sapanisertib, 10 nM each). All experiments were performed in triplicates. F) End point viability of TEADi-sensitive and -resistant cell lines upon treatment with TEADi (IAG-933, 200 nM) or FAKi (TAE226, 500 nM). Error bars show SEM (A, B, E, F). Analysis was done using an ordinary one-way ANOVA (B,F) or ordinary two-way ANOVA (A, E, comparison at last time point) with multiple comparisons testing. Synergy analysis for two-way treatments was done with SynergyFinder3.0.
Torin 2 Cayman 14185, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/torin 2 cayman 14185/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
torin 2 cayman 14185 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


A-B) Growth curves (A) and end point viability (B) of TEADi-sensitive or -resistant meningioma cell lines upon co-treatment with combinations of TEADi (IAG-933, 200 nM (sensitive lines) or 500 nM (resistant lines)), PI3Ki (pictilisib, 50 nM), MEKi (trametinib), or mTORi (torin-2). All experiments were performed in triplicates. C) Synergy plots for TEADi/MEKi or TEADi/mTORi combination treatments of TEADi-sensitive (KT21-MG1) or -resistant (IOMM-Lee) meningioma cell lines. D) Western Blot showing activation of MAPK (p-ERK), PI3K-AKT (p-AKT), or mTOR-S6 (p-S6) pathways in TEADi-resistant IOMM-Lee cells upon treatment with TEADi (IAG-933), MEKi (trametinib), mTORi (torin-2), or PI3Ki (pictilisib) in various combinations. Actin was used as a loading control. E) Growth curves of TEADi-resistant CH-157MN cells upon treatment with TEADi (IAG-933, 200 nM) or additional mTOR inhibitors (torin-2, rapamycin, vistusertib, everolimus, sapanisertib, 10 nM each). All experiments were performed in triplicates. F) End point viability of TEADi-sensitive and -resistant cell lines upon treatment with TEADi (IAG-933, 200 nM) or FAKi (TAE226, 500 nM). Error bars show SEM (A, B, E, F). Analysis was done using an ordinary one-way ANOVA (B,F) or ordinary two-way ANOVA (A, E, comparison at last time point) with multiple comparisons testing. Synergy analysis for two-way treatments was done with SynergyFinder3.0.

Journal: bioRxiv

Article Title: Comprehensive analysis of TEAD inhibition in meningioma identifies MEK and mTOR inhibition as effective combination therapies against resistant lines

doi: 10.64898/2026.03.20.713271

Figure Lengend Snippet: A-B) Growth curves (A) and end point viability (B) of TEADi-sensitive or -resistant meningioma cell lines upon co-treatment with combinations of TEADi (IAG-933, 200 nM (sensitive lines) or 500 nM (resistant lines)), PI3Ki (pictilisib, 50 nM), MEKi (trametinib), or mTORi (torin-2). All experiments were performed in triplicates. C) Synergy plots for TEADi/MEKi or TEADi/mTORi combination treatments of TEADi-sensitive (KT21-MG1) or -resistant (IOMM-Lee) meningioma cell lines. D) Western Blot showing activation of MAPK (p-ERK), PI3K-AKT (p-AKT), or mTOR-S6 (p-S6) pathways in TEADi-resistant IOMM-Lee cells upon treatment with TEADi (IAG-933), MEKi (trametinib), mTORi (torin-2), or PI3Ki (pictilisib) in various combinations. Actin was used as a loading control. E) Growth curves of TEADi-resistant CH-157MN cells upon treatment with TEADi (IAG-933, 200 nM) or additional mTOR inhibitors (torin-2, rapamycin, vistusertib, everolimus, sapanisertib, 10 nM each). All experiments were performed in triplicates. F) End point viability of TEADi-sensitive and -resistant cell lines upon treatment with TEADi (IAG-933, 200 nM) or FAKi (TAE226, 500 nM). Error bars show SEM (A, B, E, F). Analysis was done using an ordinary one-way ANOVA (B,F) or ordinary two-way ANOVA (A, E, comparison at last time point) with multiple comparisons testing. Synergy analysis for two-way treatments was done with SynergyFinder3.0.

Article Snippet: Inhibitors were purchased from MedChemExpress (MCE), Sigma-Aldrich (SA), or SelleckChem (SC) (IAG-933 (MCE HY-153811; SC E1490); MYF-03-176 (SA SML3686-5MG); GNE-7883 (MCE HY-147214), K-975 (MCE HY-138565); trametinib (MCE HY-10999); torin-2 (MCE HY-13002); pictilisib (MCE HY-50094); vistusertib (MCE HY-15247); everolimus (MCE HY-10218); rapamycin (MCE HY-10219); sapanisertib (MCE HY-13328).

Techniques: Western Blot, Activation Assay, Control, Comparison